deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00546793

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients With CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Sponsor: Gilead Sciences

Conditions CLL Leukemia, B-Cell, Chronic Leukemia, Lymphocytic, Chronic Leukemia, Prolymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Intermediate-Grade Lymphoma, Large-Cell Lymphoma, Low-Grade Lymphoma, Lymphoplasmacytoid, CLL Lymphoma, Mixed-Cell Lymphoma, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Small-Cell Lymphoplasmacytoid Lymphoma, CLL NHL SLL
Interventions veltuzumab
Updated 8 times since 2017 Last updated: Aug 12, 2021 Started: Jan 31, 2008 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on CLL and Leukemia, B-Cell, Chronic, this trial is completed. The trial is conducted by Gilead Sciences and has accumulated 8 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotCompleted~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Sep 2021 — Apr 2022 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gilead Sciences
Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations